The Evidence for Sparsentan-Mediated Inhibition of I(Na) and I(K(erg)): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor

Sparsentan is viewed as a dual antagonist of endothelin type A (ET(A)) receptor and angiotensin II (AngII) receptor and it could be beneficial in patients with focal segmental glomerulosclerosis. Moreover, it could improve glomerular filtration rate and augment protective tissue remodeling in mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Tzu-Hsien, Cho, Hsin-Yen, Wu, Sheng-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773265/
https://www.ncbi.nlm.nih.gov/pubmed/35052766
http://dx.doi.org/10.3390/biomedicines10010086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773265/
https://www.ncbi.nlm.nih.gov/pubmed/35052766
http://dx.doi.org/10.3390/biomedicines10010086

Ejemplares similares